LysRs-IN-2 is a lysyl-tRNA synthetase (KRS) inhibitor with IC50s of 0.015 μM and 0.13 μM for Plasmodium falciparum lysyl-tRNA synthetase (PfKRS) and Cryptosporidium parvum lysyl-tRNA synthetase (CpKRS), respectively.
IC50&Target
IC50: 0.015 μM (PfKRS), 0.13 μM (CpKRS)
体外研究
LysRs-IN-2 is active against whole-cell bloodstream P. falciparum 3D7 (EC50=0.27 μM), HsKRS (IC50=1.8 μM), HepG2 cells (EC50=49 μM), and Cryptosporidium parvum (EC50=2.5 µM).
体内研究
LysRs-IN-2 (1.5 mg/kg; orally once a day for 4 days) reduces parasitemia by 90% in the murine P. falciparum SCID model. LysRs-IN-2 (20 mg/kg; orally once a day for 7 days) reduces parasite shedding in NOD SCID gamma mice and INF-γ-knockout mice (Cryptosporidium mouse models).
Animal Model:
Murine P. falciparum NODscidIL2Rγnull (SCID) model
Dosage:
1.5 mg/kg
Administration:
Orally once a day for 4 days
Result:
Reduced parasitemia by 90% in the malaria SCID mouse model.
Animal Model:
NOD SCID gamma and INF-γ–knockout mouse models (Cryptosporidium mouse models)
Dosage:
20 mg/kg
Administration:
Orally once a day for 7 days
Result:
Reduced parasite shedding below detection level, and this reduction was sustained for 3 wk after treatment had stopped in INF-γ-knockout mice.
Dosed orally at a concentration of 20 mg/kg once a day for 7 days showed 96% reduction of parasite shedding comparable to paromomycin in NOD SCID gamma mice.
分子量
355.31
CAS号
2170696-76-9
运输条件
Room temperature in continental US; may vary elsewhere.